Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows:
伊利諾伊州鹿園，2024年5月1日（GLOBE NEWSWIRE）——專注於開發和商業化罕見疾病療法的創新制藥公司伊頓製藥公司（納斯達克股票代碼：ETON）今天宣佈，首席執行官肖恩·布林傑爾森和首席財務官詹姆斯·格魯伯將在紐約Citizens JMP生命科學會議上發表講話如下：
| Date: | Monday, May 13, 2024 |
| Time: | 10:00am ET |
| Webcast: | Click Here |
| 日期： | 2024 年 5 月 13 日，星期一 |
| 時間： | 美國東部時間上午10點 |
| 網絡直播： | 點擊這裏 |
To schedule a 1x1 meeting with the Company, please contact your Citizens JMP institutional sales representative.
要安排與公司的1x1會議，請聯繫您的Citizens JMP機構銷售代表。
About Eton Pharmaceuticals
關於伊頓製藥
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
伊頓是一家創新制藥公司，專注於開發和商業化罕見疾病的治療方法。該公司目前有五種商業罕見病產品：ALKINDI SPRINKLE，PKU GOLIKE、葡萄糖酸、無水甜菜鹼和尼替西農。該公司還有另外三款候選產品處於後期開發階段：ET-400、ET-600 和 ZENEO 氫化可的松自動注射器。欲了解更多信息，請訪問我們的網站 www.etonpharma.com。
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
投資者關係：
麗莎·威爾遜，現場通信公司
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
資料來源：伊頓製藥。
Source: Eton Pharmaceuticals
來源：伊頓製藥
譯文內容由第三人軟體翻譯。